All In Biotech

Drug Trial Radar · NCT01332695

A Pilot Efficacy and Safety Study of ST101 in Essential Tremor

A Randomized, Double-Blind, Placebo-Controlled, Cross-Over, Safety, Tolerability and Proof of Concept Study of ST101 for Essential Tremor

Last checked: Nov 19, 2026Latest source record: Jan 6, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

25

Actual

Start

Apr 2011

Primary completion

Dec 2011

Study completion Dec 2011

Sponsor

Lead sponsor
Sonexa Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Apr 11, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Crossover
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will look at the ability of ST101 to treat symptoms in subjects with Essential Tremor. This study will also examine the safety and tolerability of the drug. This study is evaluating one dose level of ST101 versus placebo in a cross-over fashion. This means that all patients will receive both ST101 and placebo, but they will receive it in a random (by chance) order.

Conditions

  • Essential Tremor

Interventions

  • ST101Drug

    tablets for oral administration

  • PlaceboDrug

    placebo to match

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Washington Heights-Inwood Genetic Study of Essential Tremor (WHIGET) Rating ScaleTime frame: Baseline, Week 3, Week 5, Week 8

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Los Angeles, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.